Who are they?
Dermata is a clinical-stage biotechnology company founded in late 2014 focused on the treatment of multiple medical and aesthetic skin conditions and diseases with high unmet needs.
Announced the closing of its previously announced initial public offering of 2,571,428 shares of its common stock and accompanying warrants to purchase up to 2,571,428 shares of common stock. Each share of common stock was sold together with one warrant to purchase one share of common stock with an exercise price of $7.00 per share at a combined offering price of $7.00, for gross proceeds of approximately $18.0 million.
Pipeline / Catalysts
- Phase 1 approval for Hyperhidrosis: Dermata Therapeutics Announces Positive Results from a Phase 1 Clinical Trial of DMT410, A New Topical Delivery Mechanism for Botulinum Toxin. Click for reference link.
"DMT410 is a combination regimen for the treatment of skin diseases and aesthetic conditions, by first topically applying DMT310 to the skin, followed by topical application of botulinum toxin."
- Clearly using a successful DMT 310 + Botulinum Toxin (BTX) for the DMT 410 Phase 1 Hyperhidrosis which already had a positive data. Expecting similar results for the Phase 1b POC results for Aesthetics that will be announced in Q3 2021 (September 2021).
Large Holders
Technicals
Comments
Post a Comment